492 completed, 138 terminated, 127 recruiting, 114 unknown. 641 Phase 2, 311 Phase 1, 120 Phase 3, 19 Not applicable, 7 Phase 4.
Follow Cetuximab: new trials by email Literature Review of Cetuximab trials Research Report on Cetuximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Real-World Study: Panitumumab N01 vs Cetuximab Plus FOLFOX in First-Line RAS Wild-Type mCRC Panitumumab N01, Cetuximab (EGFR inhibitor) - Colorectal Cancer Metastatic | Not yet recruiting | Fujian Medical University Union Hospital | 610 | 2027-01-01 | 2026-11-04 | |
| A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) Mutation RO7836748, Pembrolizumab, mFOLFIRINOX - Solid Tumors | Phase 1 | Not yet recruiting | Hoffmann-La Roche | 540 | 2026-12-31 | 2026-10-30 |
| A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D Mutation BI 4015092, Cetuximab - Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Phase 1 | Not yet recruiting | Boehringer Ingelheim | 200 | 2026-12-07 | 2026-11-09 |
| Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma Cemiplimab, Prednisone, Sirolimus - Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 2 | Not yet recruiting | Washington University School of Medicine | 22 | 2026-11-30 | 2026-10-15 |
| A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies BMS-986548, Cetuximab - Advanced Solid Malignancies | Phase 1 / Phase 2 | Not yet recruiting | Bristol-Myers Squibb | 171 | 2026-11-30 | 2026-11-16 |
| A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer Irinotecan, Oxaliplatin, GFH276 - CRC | Phase 1 / Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 150 | 2026-11-15 | 2026-11-06 |
| A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors PF-08165784, Fulvestrant, Atirmociclib - Advanced Breast Cancer, Advanced or Metastatic Breast Cancer | Phase 1 | Not yet recruiting | Pfizer | 268 | 2026-11-09 | 2026-10-28 |
| IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors IL-12 GEMys, Cyclophosphamide, Fludarabine - Relapsed Solid Tumor Malignancies, Refractory Solid Tumor Malignancies | Phase 1 | Recruiting | National Cancer Institute (NCI) | 95 | 2026-11-04 | 2026-11-16 |
| FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II) Oxaliplatin, 5-Fluorouracil, Levofolinic Acid For Injection - Metastatic Colorectal Cancer (CRC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 229 | 2026-11-01 | 2026-10-16 |
| GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer GFH375 + Cetuximab, Fruquintinib, Trifluridine and Tipiracil - Colorectal Cancer | Phase 3 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 368 | 2026-11-01 | 2026-11-03 |
| Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma Cetuximab, Cemiplimab - Locally Advanced Cutaneous Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Melanoma and Skin Cancer Trials Limited | 27 | 2026-10-30 | 2026-10-07 |
| A KRAS Inhibitor in Participants With Advanced Solid Tumors ETX-929 dose escalation, ETX-929 dose escalation in combination with cetuximab - Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 / Phase 2 | Recruiting | Ensem Therapeutics | 320 | 2026-10-22 | 2026-11-12 |
| Iparomlimab and Tuvonralimab With With Cetuximab in Resectable OSCC iparomlimab and tuvonralimab combined with cetuximab - Head and Neck Cancer | Phase 2 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 26 | 2026-10-16 | 2026-10-20 |
| A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) Combined With Cetuximab and mFOLFIRI Regimen as First-Line Treatment for Recurrent or Metastatic Colorectal Cancer QL1706 combined with cetuximab and mFOLFIRI - Colorectal Cancer | Not applicable | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 55 | 2026-10-08 | 2026-10-14 |
| Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) Petosemtamab, Cetuximab, Bevacizumab - Colorectal Cancer | Phase 3 | Recruiting | Genmab | 600 | 2026-10-07 | 2026-11-16 |
| Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients FOLFIRI+cetuximab, Guardant360 ctDNA assay - Colorectal Cancer Metastatic | Phase 3 | Not yet recruiting | Charite University, Berlin, Germany | 267 | 2026-10-01 | 2026-07-29 |
| A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation Olomorasib, Cetuximab, Oxaliplatin - Colorectal Neoplasms | Phase 2 | Not yet recruiting | Eli Lilly and Company | 50 | 2026-10-01 | 2026-10-15 |
| A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma CRB-701, capcitabine, Cetuximab (EGFR inhibitor) - Oropharyngeal Carcinoma (OPC) | Phase 3 | Recruiting | Corbus Pharmaceuticals Inc. | 260 | 2026-09-29 | 2026-10-08 |
| Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status Cetuximab (EGFR inhibitor), Bevacizumab, Irinotecan (CPT-11) - Colorectal Cancer | Phase 4 | Not yet recruiting | Gruppo Oncologico del Nord-Ovest | 280 | 2026-09-15 | 2026-07-24 |
| A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects HC034S, Erbitux (Cetuximab) - Cetuximab, Bioequivalence | Phase 1 | Recruiting | HC Biopharma Inc. | 92 | 2026-09-12 | 2026-11-04 |
Showing 20 of 989. Sign in to see all of them.
Colorectal Neoplasms (331) · Squamous Cell Carcinoma of Head and Neck (170) · Head and Neck Neoplasms (152) · Carcinoma, Non-Small-Cell Lung (100) · Colonic Neoplasms (94) · Rectal Neoplasms (83) · Neoplasm Metastasis (75) · Neoplasms (60) · Pancreatic Neoplasms (43) · Carcinoma, Squamous Cell (40) · Lung Neoplasms (36) · Esophageal Neoplasms (25) · Breast Neoplasms (23) · Recurrence (21) · Stomach Neoplasms (20)
Eli Lilly and Company (46) · National Cancer Institute (NCI) (38) · M.D. Anderson Cancer Center (31) · Merck KGaA, Darmstadt, Germany (30) · Memorial Sloan Kettering Cancer Center (19) · Fudan University (18) · Merck Sharp & Dohme LLC (16) · Bristol-Myers Squibb (15) · Sun Yat-sen University (15) · Pfizer (14) · Alliance for Clinical Trials in Oncology (11) · Hoffmann-La Roche (11) · Washington University School of Medicine (11) · Dana-Farber Cancer Institute (10) · Groupe Oncologie Radiotherapie Tete et Cou (10)
United States (505) · France (140) · China (137) · Spain (115) · Italy (104) · Germany (89) · Canada (76) · South Korea (74) · United Kingdom (73) · Australia (71) · Belgium (62) · Netherlands (51) · Japan (46) · Taiwan (42) · Poland (41)
Douglas Adkins, M.D. (7) · Tanguy Seiwert (4) · Ari Rosenberg, MD (3) · Barbara A. Burtness, MD (3)
PMID 25057165, PMID 16467544, PMID 19339720, PMID 19897418, PMID 23265711, PMID 27722750, PMID 28797458, PMID 30466310, PMID 30944020, PMID 31268130, PMID 33356421, PMID 33684371, PMID 36306483, PMID 36763936, PMID 36852723, PMID 36880426, PMID 38592721, PMID 40215447, PMID 41343184, PMID 10493478, PMID 10744089, PMID 11208820, PMID 11247898, PMID 12518365, PMID 12927569, PMID 14967461, PMID 15142632, PMID 15175435, PMID 1584260, PMID 15870084, PMID 15908664, PMID 16246975, PMID 16314626, PMID 16356309, PMID 16476835, PMID 16681848, PMID 16943526, PMID 17050875, PMID 17470860, PMID 17553204, PMID 17704420, PMID 17960012, PMID 17960013, PMID 18003960, PMID 18077217, PMID 18191993, PMID 18272912, PMID 18279058, PMID 18316791, PMID 18349029
2023 (13), 2009 (12), 2025 (10), 2014 (9), 2015 (9), U10CA032102 (9), 2008 (7), U10CA021115 (7), 2016 (6), 2017 (6), 2019 (6), U10CA180888 (6), P30CA068485 (5), 2018 (4), N01CM62201 (4)